Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Catalent Partnering on COVID Vaccine Effort

Thursday, June 25, 2020 04:52 PM EDT
By Alex Brown
Catalent Partnering on COVID Vaccine Effort

New Jersey-based Catalent Inc. (NYSE: CTLT) is partnering with a biotechnology company in Massachusetts to manufacture a COVID-19 vaccine candidate. The company says the deal with Moderna Inc. (Nasdaq: MRNA) will involve manufacturing, vial filling and packaging at its biologics facility in Bloomington.

Catalent says the commercial fill-finish manufacturing operations will run 24 hours a day, 7 days a week, which will require additional staffing. However, a specific number of new employees was not provided.

The effort is expected to produce an initial 100 million doses of the vaccine candidate for the U.S. market, beginning in the third quarter.

“Catalent is proud to partner with Moderna in its work to address this critical public health need,” John Chiminski, chief executive officer of Catalent, said in a news release. “Catalent’s proven expertise in manufacturing scale-up and commercial production are well suited to support Moderna’s efforts to prepare for wide-scale supply of this vaccine candidate so that it is available if appropriate to address the pandemic.”

Catalent says it will also provide clinical supply services from its Philadelphia facilities to support Moderna’s Phase 3 clinical study for the vaccine candidate.

In April, Catalent reached a deal with a subsidiary of Johnson & Johnson (NYSE: JNJ) for large scale manufacturing of J&J’s lead COVID-19 vaccine candidate. The company said it plans to add 300 jobs as a result.

Business of Health Reporter Kylie Veleta spotlighted the partnership in a recent edition of the Life Sciences INdiana newsletter, which you can read by clicking here.

Story Continues Below

Most Popular Stories

  • Commercial air service slated to return to Purdue Airport

  • Why the NCAA president is proposing some schools should be permitted to pay athletes

  • Purdue board approves business school construction, tuition freeze

  • Appeals court again rules against couple operating shooting range

  • Indiana judge rules in favor of Senate candidate seeking GOP nomination

  • SBA awards $728M to Hoosier entrepreneurs in 2023

Perspectives

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

In the hustle and bustle of our professional lives, we often find ourselves engrossed in the intricacies of our trades. However, amidst our daily routines, there exists a unique opportunity to broaden our horizons and delve into the critical issues facing the state of Indiana. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service